Effect of eplerenone on parathyroid hormone levels in patients with primary hyperparathyroidism: results from the Epath randomized, placebo-controlled trial
Accumulating evidence points toward mutual interaction between parathyroid hormone (PTH) and aldosterone as potential mechanism for increasing cardiovascular risk in primary hyperparathyroidism (pHPT). The Eplerenone on parathyroid hormone levels in patients with primary hyperparathyroidism (EPATH)...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
11 March 2016
|
| In: |
Journal of hypertension
Year: 2016, Jahrgang: 34, Heft: 7, Pages: 1347-1356 |
| ISSN: | 1473-5598 |
| DOI: | 10.1097/HJH.0000000000000927 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1097/HJH.0000000000000927 Verlag, Volltext: https://insights.ovid.com/pubmed?pmid=27065001 
|
| Verfasserangaben: | Andreas Tomaschitz, Nicolas Verheyen, Andreas Meinitzer, Burkert Pieske, Evgeny Belyavskiy, Helmut Brussee, Josef Haas, Winfried März, Elisabeth Pieske-Kraigher, Sarah Verheyen, Lisa Ofner-Ziegenfuss, Bríain Ó Hartaigh, Verena Schwetz, Felix Aberer, Martin Grübler, Florian Lang, Ioana Alesutan, Jakob Voelkl, Martin Gaksch, Jörg H. Horina, Hans-Peter Dimai, Jutta Rus-Machan, Claudia Stiegler, Eberhard Ritz, Astrid Fahrleitner-Pammer, and Stefan Pilz |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1569844550 | ||
| 003 | DE-627 | ||
| 005 | 20220814073243.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180214s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/HJH.0000000000000927 |2 doi | |
| 035 | |a (DE-627)1569844550 | ||
| 035 | |a (DE-576)499844556 | ||
| 035 | |a (DE-599)BSZ499844556 | ||
| 035 | |a (OCoLC)1340987102 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Tomaschitz, Andreas |e VerfasserIn |0 (DE-588)106940036X |0 (DE-627)821859072 |0 (DE-576)428670458 |4 aut | |
| 245 | 1 | 0 | |a Effect of eplerenone on parathyroid hormone levels in patients with primary hyperparathyroidism |b results from the Epath randomized, placebo-controlled trial |c Andreas Tomaschitz, Nicolas Verheyen, Andreas Meinitzer, Burkert Pieske, Evgeny Belyavskiy, Helmut Brussee, Josef Haas, Winfried März, Elisabeth Pieske-Kraigher, Sarah Verheyen, Lisa Ofner-Ziegenfuss, Bríain Ó Hartaigh, Verena Schwetz, Felix Aberer, Martin Grübler, Florian Lang, Ioana Alesutan, Jakob Voelkl, Martin Gaksch, Jörg H. Horina, Hans-Peter Dimai, Jutta Rus-Machan, Claudia Stiegler, Eberhard Ritz, Astrid Fahrleitner-Pammer, and Stefan Pilz |
| 264 | 1 | |c 11 March 2016 | |
| 300 | |a 10 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 14.02.2018 | ||
| 520 | |a Accumulating evidence points toward mutual interaction between parathyroid hormone (PTH) and aldosterone as potential mechanism for increasing cardiovascular risk in primary hyperparathyroidism (pHPT). The Eplerenone on parathyroid hormone levels in patients with primary hyperparathyroidism (EPATH) trial is a single-center, randomized, double-blind, parallel-group, placebo-controlled trial. The primary aim is to evaluate the effects of the mineralocorticoid receptor antagonist eplerenone on plasma intact PTH (iPTH) concentration in patients with pHPT. Secondary end points comprised surrogate parameters of cardiovascular health [24-h ambulatory SBP and DBP and echocardiographic parameters related to systolic/diastolic function as well as to cardiac dimensions]. We enrolled 110 study participants with pHPT, 25-hydroxyvitamin D at least 20 ng/ml and estimated glomerular filtration rate more than 50 ml/min per 1.73 m2. Patients were 1 : 1 randomly assigned to receive either 25 mg eplerenone once daily (up-titration after 4 weeks to 50 mg/day) or matching placebo for a treatment period of 8 weeks. The study was completed by 97 participants [mean (SD) age: 67.5 ± 9.5 years; 78.4% women). The mean treatment effect (95% confidence interval) for iPTH was 1.0 (0.9-1.1; P = 0.777) pg/ml. Mean 24-h ambulatory SBP and DBP decreased significantly [mean change (95% confidence interval) −6.3 (−9.4 to −3.3) and −3.7 (−5.7 to −1.7) mmHg, respectively; P < 0.001]. No differences were seen in any further secondary outcomes or frequency of adverse events. In pHPT, treatment with eplerenone compared with placebo had no effect on circulating iPTH levels. Eplerenone treatment was well tolerated and safe and followed by significant decrease of ambulatory blood pressure. | ||
| 700 | 1 | |a März, Winfried |d 1958- |e VerfasserIn |0 (DE-588)1027603599 |0 (DE-627)729463605 |0 (DE-576)373454635 |4 aut | |
| 700 | 1 | |a Ritz, Eberhard |d 1938-2023 |e VerfasserIn |0 (DE-588)106673386 |0 (DE-627)610528866 |0 (DE-576)311552501 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of hypertension |d London : Lippincott, Williams & Wilkins, 1983 |g 34(2016), 7, Seite 1347-1356 |h Online-Ressource |w (DE-627)320581373 |w (DE-600)2017684-3 |w (DE-576)091014018 |x 1473-5598 |7 nnas |a Effect of eplerenone on parathyroid hormone levels in patients with primary hyperparathyroidism results from the Epath randomized, placebo-controlled trial |
| 773 | 1 | 8 | |g volume:34 |g year:2016 |g number:7 |g pages:1347-1356 |g extent:10 |a Effect of eplerenone on parathyroid hormone levels in patients with primary hyperparathyroidism results from the Epath randomized, placebo-controlled trial |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/HJH.0000000000000927 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://insights.ovid.com/pubmed?pmid=27065001 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180214 | ||
| 993 | |a Article | ||
| 994 | |a 2016 | ||
| 998 | |g 106673386 |a Ritz, Eberhard |m 106673386:Ritz, Eberhard |d 910000 |d 910100 |e 910000PR106673386 |e 910100PR106673386 |k 0/910000/ |k 1/910000/910100/ |p 24 | ||
| 998 | |g 1027603599 |a März, Winfried |m 1027603599:März, Winfried |d 60000 |d 61400 |e 60000PM1027603599 |e 61400PM1027603599 |k 0/60000/ |k 1/60000/61400/ |p 8 | ||
| 999 | |a KXP-PPN1569844550 |e 2999312903 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"origin":[{"dateIssuedKey":"2016","dateIssuedDisp":"11 March 2016"}],"note":["Gesehen am 14.02.2018"],"recId":"1569844550","name":{"displayForm":["Andreas Tomaschitz, Nicolas Verheyen, Andreas Meinitzer, Burkert Pieske, Evgeny Belyavskiy, Helmut Brussee, Josef Haas, Winfried März, Elisabeth Pieske-Kraigher, Sarah Verheyen, Lisa Ofner-Ziegenfuss, Bríain Ó Hartaigh, Verena Schwetz, Felix Aberer, Martin Grübler, Florian Lang, Ioana Alesutan, Jakob Voelkl, Martin Gaksch, Jörg H. Horina, Hans-Peter Dimai, Jutta Rus-Machan, Claudia Stiegler, Eberhard Ritz, Astrid Fahrleitner-Pammer, and Stefan Pilz"]},"relHost":[{"pubHistory":["1.1983 -"],"part":{"issue":"7","pages":"1347-1356","text":"34(2016), 7, Seite 1347-1356","volume":"34","extent":"10","year":"2016"},"id":{"eki":["320581373"],"issn":["1473-5598"],"zdb":["2017684-3"]},"type":{"media":"Online-Ressource","bibl":"periodical"},"recId":"320581373","origin":[{"dateIssuedKey":"1983","publisherPlace":"London","dateIssuedDisp":"1983-","publisher":"Lippincott, Williams & Wilkins"}],"language":["eng"],"title":[{"title":"Journal of hypertension","subtitle":"official journal of International Society of Hypertension, European Society of Hypertension","title_sort":"Journal of hypertension"}],"physDesc":[{"extent":"Online-Ressource"}],"note":["Gesehen am 27.11.20","Ungezählte Beil.: Suppl"],"disp":"Effect of eplerenone on parathyroid hormone levels in patients with primary hyperparathyroidism results from the Epath randomized, placebo-controlled trialJournal of hypertension"}],"title":[{"title":"Effect of eplerenone on parathyroid hormone levels in patients with primary hyperparathyroidism","subtitle":"results from the Epath randomized, placebo-controlled trial","title_sort":"Effect of eplerenone on parathyroid hormone levels in patients with primary hyperparathyroidism"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"id":{"eki":["1569844550"],"doi":["10.1097/HJH.0000000000000927"]},"physDesc":[{"extent":"10 S."}],"language":["eng"],"person":[{"family":"Tomaschitz","given":"Andreas","display":"Tomaschitz, Andreas","role":"aut"},{"role":"aut","display":"März, Winfried","given":"Winfried","family":"März"},{"family":"Ritz","given":"Eberhard","display":"Ritz, Eberhard","role":"aut"}]} | ||
| SRT | |a TOMASCHITZEFFECTOFEP1120 | ||